PMID- 32104590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2081-3856 (Print)
IS  - 2081-6936 (Electronic)
IS  - 2081-6936 (Linking)
VI  - 11
DP  - 2020
TI  - Anticholinergic Drugs and Oral Health-related Quality of Life in Patients with 
      Schizophrenia: A Pilot Study.
PG  - 10-16
LID - 10.1515/tnsci-2020-0003 [doi]
AB  - OBJECTIVE: The aim of this study was to explore, in a sample population of people 
      with schizophrenia (PWS), the role of the anticholinergic burden on the 
      perception of oral health-related quality of life (OHrQoL) in France. METHODS: A 
      pilot study was performed between March 2014 and January 2016. PWS were recruited 
      from a population in Cote d'Or department in France. Dental status was 
      investigated using the Decayed, Missing, or Filled Teeth (DMFT) index, the 
      Xerostomia Index (XI), and the Global Oral Health Assessment Index (GOHAI) for 
      OHrQoL. The anticholinergic impregnation score was recorded using the 
      anticholinergic impregnation scale (AIS). RESULTS: A sample of 62 people was 
      selected. The DMFT score was 16.5+/- 8.7, the XI score was 22.9+/-7.8, the GOHAI 
      score was 43.0+/-8.8, and the AIS score was 3.1+/-2.8. In total, 169 drugs were 
      prescribed to the people of our sample, and 114 different anticholinergic drugs 
      were observed. The most frequently used anticholinergic drugs (51.40%), in the 
      study had a low antimuscarinic potency (1 point according to AIS scale). The 
      multiple linear regression model showed that the OHrQoL scores were significantly 
      lower when the DMFT scores, XI score, and anticholinergic scores were high. 
      CONCLUSIONS: This pilot study highlighted the potential role of the 
      anticholinergic burden on the OHrQoL of PWS. A study with a validated specific 
      scale for the OHrQoL and a standard anticholinergic burden scale should be 
      conducted to clarify the role of anticholinergic drugs on the OHrQoL for PWS.
CI  - (c) 2020 Joseph Antony, et al. published by De Gruyter.
FAU - Chapuis, Justine
AU  - Chapuis J
AD  - University Hospital of Tours ,Odontology Department, 37170 Chambray-les-Tours, 
      France.
FAU - Siu-Paredes, Francesca
AU  - Siu-Paredes F
AD  - EA 481 Integrative Neurosciences and Clinical. University Hospital of Besancon, 
      25000 Besancon, France.
AD  - Universite Champagne Ardenne. Faculte d'odontologie de Reims, 51100 Reims, 
      France.
FAU - Pavageau, Claire
AU  - Pavageau C
AD  - University Hospital of Tours. Service d'odontologie du CHU de Tours, 37170 
      Chambray-les-Tours, France.
FAU - Amador, Gilles
AU  - Amador G
AD  - Universite de Nantes, Faculte d'Odontologie de Nantes, 44000 Nantes, France.
FAU - Rude, Nathalie
AU  - Rude N
AD  - EA 481 Integrative Neurosciences and Clinical. University Hospital of Besancon, 
      25000 Besancon, France.
FAU - Denis, Frederic
AU  - Denis F
AD  - University Hospital of Tours ,Odontology Department, 37170 Chambray-les-Tours, 
      France.
AD  - Universite de Nantes, Faculte d'Odontologie de Nantes, 44000 Nantes, France.
AD  - EA 75-05 Education, Ethique, Sante. Universite de Tours, Faculte de Medecine, 
      37032 Tours, France.
LA  - eng
PT  - Journal Article
DEP - 20200211
PL  - Germany
TA  - Transl Neurosci
JT  - Translational neuroscience
JID - 101550327
PMC - PMC7029653
OTO - NOTNLM
OT  - anticholinergic drugs
OT  - oral disease
OT  - oral health
OT  - oral health related quality of life
OT  - schizophrenia
COIS- Conflict of interest: Authors state no conflict of interest.
EDAT- 2020/02/28 06:00
MHDA- 2020/02/28 06:01
PMCR- 2020/02/11
CRDT- 2020/02/28 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/01/16 00:00 [accepted]
PHST- 2020/02/28 06:00 [entrez]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2020/02/28 06:01 [medline]
PHST- 2020/02/11 00:00 [pmc-release]
AID - tnsci-2020-0003 [pii]
AID - 10.1515/tnsci-2020-0003 [doi]
PST - epublish
SO  - Transl Neurosci. 2020 Feb 11;11:10-16. doi: 10.1515/tnsci-2020-0003. eCollection 
      2020.